N-Methyl-2,2,3,3-tetramethyl-succinimid | 60345-33-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Methyl-2,2,3,3-tetramethyl-succinimid
• 英文别名: 1,3,3,4,4-Pentamethylpyrrolidine-2,5-dione
• CAS: 60345-33-7
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: QEEDSPCJHOIXHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Methyl-2,2,3,3-tetramethyl-succinimid 以48%的产率得到
  参考文献：
  名称：

  SCHLECKER R.; SEEBACH D., HELV. CHIM. ACTA , 1977, 60, NO 5, 1459-1471

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴-3,3,4,4-四甲基吡咯烷-2,5-二酮 、 对甲苯磺酸甲酯 以88%的产率得到N-Methyl-2,2,3,3-tetramethyl-succinimid
  参考文献：
  名称：

  N-溴琥珀酰亚胺-琥珀酰亚胺阴离子络合物，是电子转移介导的琥珀酰亚胺阴离子还原N-溴琥珀酰亚胺的中间体

  摘要：

  N-溴琥珀酰亚胺和琥珀酰亚胺阴离子之间的络合物显示为还原N-溴琥珀酰亚胺的中间体，并描述了其合成为四正丁基铵盐的方法。

  DOI：

  10.1016/s0040-4039(01)81306-x

文献信息

• PHTHALAZINONE DERIVATIVES
  申请人：Javaid Muhammad Hashim

  公开号：US20080255128A1

  公开（公告）日：2008-10-16

  A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; X is selected from H and F; R 1 and R 2 are independently selected from H and methyl; R N1 is selected from H and optionally substituted C 1-7 alkyl; R N2 is selected from H, optionally substituted C 1-7 alkyl, C 3-7 heterocyclyl and C 5-6 aryl; or R N1 and R N2 and the nitrogen atom to which they are bound form an optionally substituted nitrogen containing C 5-7 heterocyclic group.

  式(I)的化合物：其中：A和B一起代表一个可选择取代的、融合的芳香环；X从H和F中选择；R1和R2分别从H和甲基中选择；RN1从H和可选择取代的C1-7烷基中选择；RN2从H、可选择取代的C1-7烷基、C3-7杂环烷基和C5-6芳基中选择；或者RN1和RN2和它们结合的氮原子形成一个可选择取代的含氮C5-7杂环基。
• RUTHENIUM-BASED CATALYTIC COMPLEXES AND THE USE OF SUCH COMPLEXES FOR OLEFIN METATHESIS
  申请人：Mauduit Marc

  公开号：US20100087644A1

  公开（公告）日：2010-04-08

  The invention relates to all compounds of the formula (I) or (II) in which: L is a neutral ligand; X, X′ are anionic ligands; R 1 and R 2 are, separately, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 perhalogenoalkyl, a aldehyde, a ketone, an ester, a nitrile, an aryl, a pyridinium alkyl, an optionally substituted C 5 or C 6 pyridinium alkyl, perhalogenoalkyl or cyclohexyl, a C n h2 N Y radical 10 with n between 1 and 6 and y an i8onic marker, or a radical having the formula: wherein R 1 can be a radical of formula (Ibis) when the compound has formula (I) or of formula (IIbis) when the compound has formula (II), R 3 is a C 1 -C 6 alkyl, or a C 5 or C 6 cycloalkyl or a C 5 or C 6 aryl; R 0 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , are, separately, a hydrogen, C 1 -C 6 alkyl, a C 1 -C 6 perhalogenoalkyl, or a C 5 or C 6 aryl; wherein R 9 , R 10 , R 11 can be a heterocycle; X 1 is anion. R 1 and R 2 can form, with the N and the C to which they are attached, a heterocycle.

  本发明涉及公式（I）或（II）中的所有化合物，其中：L为中性配体；X，X'为阴离子配体；R1和R2分别为氢，C1-C6烷基，C1-C6全氟烷基，醛，酮，酯，腈，芳基，吡啶基烷基，可选取代的C5或C6吡啶基烷基，全氟烷基或环己基，Cnh2NY基团10，其中n在1至6之间，y为离子标记，或具有以下公式的基团：其中当化合物具有公式（I）时，R1可以是公式（Ibis）的基团，当化合物具有公式（II）时，R1可以是公式（IIbis）的基团，R3为C1-C6烷基，或C5或C6环烷基或C5或C6芳基；R0，R4，R5，R6，R7，R8，R9，R10，R11分别为氢，C1-C6烷基，C1-C6全氟烷基或C5或C6芳基；其中R9，R10，R11可以是杂环；X1为阴离子。R1和R2可以与它们连接的N和C形成杂环。
• DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Hatayama Akira

  公开号：US20100087442A1

  公开（公告）日：2010-04-08

  The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).

  本发明涉及式(I)的二酮肼衍生物及其药学上可接受的盐（式中符号与说明书中描述的含义相同）。式(I)化合物具有对半胱氨酸蛋白酶的抑制活性，可用于治疗炎症性疾病、免疫性疾病、缺血性疾病、呼吸系统疾病、循环系统疾病、血液疾病、神经系统疾病、肝胆系统疾病、骨骼或关节疾病、代谢性疾病等。该化合物具有对弹性蛋白酶的抑制活性，也可用于治疗慢性阻塞性肺部疾病（COPD）。
• DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1498411B1

  公开（公告）日：2013-01-16
• Composition for liquid crystal aligning, liquid crystal aligning layer prepared from the same, and liquid crystal display comprising the same
  申请人：Kim Kyung-Jun

  公开号：US20070154656A1

  公开（公告）日：2007-07-05

  The present invention to a composition for liquid crystal aligning comprising an oligoimide or oligoamic acid, which comprises a thermocurable or photocurable functional group on at least one end of the oligoimide or oligoamic acid backbone, a liquid crystal aligning layer prepared from the same, and a liquid crystal display comprising the same. The composition for liquid crystal aligning according to the present can minimize the generation of the decomposed by-products, which had been generated upon the use of polyimides, by using an oligoimide or oligoamic acid on at least one end of the backbone, instead of the conventional polyimides and has an excellent effect of improvement in alignment property, thermal stability, and image sticking.